ABSTRACT
INTRODUCTION: Gyrate atrophy (GA) is a rare retinal dystrophy due to biallelic pathogenic variants in the ornithine aminotransferase (OAT) gene, causing a 10-fold increase in plasma ornithine levels. It is characterized by circular patches of chorioretinal atrophy. However, a GA-like retinal phenotype (GALRP) without elevated ornithine levels has also been reported. The aim of this study is to compare the clinical characteristics of GA and GALRP and to identify possible discriminators. METHODS: A multicenter, retrospective chart review was performed at three German referral centres on patient records between 01/01/2009 and 31/12/2021. Records were screened for patients affected by GA or GALRP. Only patients with examination results for plasma ornithine levels and / or genetic testing of the OAT gene were included. Further clinical data was gathered where available. RESULTS: Ten patients (5 female) were included in the analysis. Three suffered from GA, while seven had a GALRP. Mean age (± SD) at onset of symptoms was 12.3 (± 3.5) years for GA compared with 46.7 (± 14.0) years for GALRP patients (p = 0.002). Mean degree of myopia was higher in GA (-8.0 dpt. ± 3.6) compared to GALRP patients (-3.8 dpt. ± 4.8, p = 0.04). Interestingly, all GA patients showed macular oedema, while only one GALRP patient did. Only one patient with GALRP had a positive family history, while two were immunosuppressed. DISCUSSION: Age of onset, refraction and presence of macular cystoid cavities appear to be discriminators between GA and GALRP. GALRP may encompass both genetic and non-genetic subtypes.
Subject(s)
Gyrate Atrophy , Humans , Female , Child , Adolescent , Gyrate Atrophy/diagnosis , Gyrate Atrophy/genetics , Retrospective Studies , Retina/pathology , Phenotype , Ornithine , Atrophy/pathologyABSTRACT
Peters anomaly and Axenfeld-Rieger syndrome (ARS) belong to the overlapping spectrum of disorders summarized as anterior segment dysgenesis (ASD). Five patients from a family with Peters' anomaly and ARS were screened for mutations in the PITX2, CYP1B1 and FOXC1 genes by direct sequencing. All affected family members examined were heterozygous for a single nucleotide substitution, resulting in a nonsense mutation (Q120X) at a highly conserved residue of the FOXC1 gene that is essential for DNA binding. In this pedigree, all affected family members were diagnosed with ARS except for one who shows bilateral Peters' anomaly. Our findings support the role of FOXC1 mutations in the spectrum of ASD.
Subject(s)
Abnormalities, Multiple/genetics , Anterior Eye Segment/abnormalities , Eye Abnormalities/genetics , Forkhead Transcription Factors/genetics , Mutation , Aryl Hydrocarbon Hydroxylases , Base Sequence , Cytochrome P-450 CYP1B1 , Cytochrome P-450 Enzyme System/genetics , DNA Mutational Analysis , Family , Homeodomain Proteins/genetics , Humans , Iris/abnormalities , Molecular Sequence Data , Pedigree , Point Mutation , Syndrome , Transcription Factors/genetics , Homeobox Protein PITX2ABSTRACT
BACKGROUND: Axenfeld-Rieger syndrome (ARS) is a rare autosomal dominant disorder with an incidence of 1:200 000. Genotype and phenotype are heterogeneous and clinical morphology impresses with variable expressivity. Additionally to the typical craniofacial and dental aberrations anomalies in the morphology of sella turcica are discussed. METHOD: In a multidisciplinary genetic and clinical study four patients of a family with ARS were screened by direct DNA sequencing. Radiographic analysis of the patients was performed for evaluating cranial and dental structures. Additionally, a specific analysis of the morphology of the sella turcica was made on the radiographs. RESULTS: Screening for PITX2 and FOXC1 mutations revealed a P64L missense mutation in PITX2 in all four patients. The cephalometric analysis showed a midface hypoplasia associated with a skeletal Class III. All patients showed a sella turcica bridge combined with a prominent posterior clinoid process followed by a steep clivus and an elongated sella turcica. CONCLUSION: The incidence of a sella turcica bridge in combination with a PITX2 mutation would suspect that sella turcica anomalies are typical symptoms of the syndrome. Sella turcica anomalies in association with craniofacial and dental aberrations, such as maxillary retrognathia, skeletal Class III relationship and hypoplasia of teeth, might be important indicators for ARS caused by PITX2 mutation.
Subject(s)
Craniofacial Abnormalities/pathology , Homeodomain Proteins/genetics , Mutation, Missense/genetics , Sella Turcica/abnormalities , Tooth Abnormalities/pathology , Transcription Factors/genetics , Adolescent , Cephalometry , Chromosomes, Human, Pair 13/genetics , Codon/genetics , Cranial Fossa, Posterior/abnormalities , Craniofacial Abnormalities/genetics , Cytosine , Eye Abnormalities/pathology , Facial Bones/abnormalities , Female , Forkhead Transcription Factors/genetics , Heterozygote , Humans , Leucine/genetics , Male , Malocclusion, Angle Class III/pathology , Maxilla/abnormalities , Middle Aged , Proline/genetics , Sella Turcica/pathology , Syndrome , Thymine , Tooth Abnormalities/genetics , Young Adult , Homeobox Protein PITX2ABSTRACT
AIM: To identify novel or rare rhodopsin gene mutations in patients with autosomal dominant retinitis pigmentosa and description of their clinical phenotype. METHODS: The complete rhodopsin gene was screened for mutations by DNA sequencing in index patients. Mutation specific assays were used for segregation analysis and screening for controls. Eight patients from five families and their relatives were diagnosed with autosomal dominant retinitis pigmentosa (adRP) by means of clinical evaluation. RESULTS: Mutation screening identified five different rhodopsin mutations including three novel mutations: Ser176Phe, Arg314fs16, and Val20Gly and two missense mutations, Pro215Leu and Thr289Pro, that were only reported once in a mutation report. Electrophysiological and psychophysical testings provide evidence of an impaired rod system with additionally affected cone system in subjects from each genotype group. Visual function tended to be less affected in subjects with the Arg314fs16 and Val20Gly mutations than in the Ser176Phe phenotype. In contrast, Pro215Leu and Thr289Pro mutations caused a remarkably severe phenotype. CONCLUSION: The ophthalmic findings support a correlation between disease expression and structural alteration: (1) extracellular/intradiscal Val20Gly and cytoplasmic Arg314fs16 mutation-mild adRP phenotype; (2) Ser176Phe mutation-"mostly type 1" disease; (3) predicted alteration of transmembrane domains TM V and TM VII induced by Pro215Leu and Thr289Pro-severe phenotype. However, variation of phenotype expression in identical genotypes may still be a typical feature of RHO mutations.
Subject(s)
Mutation , Retinitis Pigmentosa/genetics , Rhodopsin/genetics , Adolescent , Adult , Age of Onset , Amino Acid Sequence , Child , Child, Preschool , DNA Mutational Analysis/methods , Female , Genes, Dominant , Genotype , Humans , Male , Middle Aged , Molecular Sequence Data , Mutation, Missense , Pedigree , Phenotype , Polymorphism, Restriction Fragment Length , Visual Acuity , Visual FieldsABSTRACT
The term glaucoma describes a heterogeneous group of optic neuropathies that lead to optic nerve atrophy and permanent loss of vision. It is the second most prevalent cause of bilateral blindness in the Western world and affects over 60 million people worldwide. The hereditary forms of glaucoma are genetically heterogeneous. Different forms of glaucoma can be distinguished: the primary open-angle glaucoma of adult onset is the most common, representing approximately half of all cases. The juvenile-onset open-angle glaucoma is an uncommon autosomal dominant form of glaucoma with manifestation predominantly before the fourth decade of life. The primary congenital glaucoma is a clinical and genetic entity clearly distinct from the juvenile form, following an autosomal recessive mode of inheritance. At least eight loci have been linked to glaucoma (GLC1A-F, GLC3A/B) and three genes have been identified to date: MYOC, CYP1B1 and OPTN. In the last decade, there has been much progress in finding new genes, detecting disease-related mutations and determining allele frequencies within populations of different ethnical backgrounds, but little is known about the function of the mutated gene products and the underlying pathogenic mechanisms. This chapter attempts to summarize the current knowledge regarding glaucoma-associated genes.
Subject(s)
Glaucoma/genetics , Eye Proteins/genetics , Genetic Linkage , Humans , Optic Nerve Diseases/geneticsABSTRACT
The glutamine synthetase II (GSII, encoded by glnII) activity detectable in crude extracts from Streptomyces coelicolor is low compared to the activity of glutamine synthetase I (GSI, encoded by glnA) and to that of GSII from S. viridochromogenes. We have identified and sequenced a 3.9-kb BglII-BamHI fragment carrying the glutamine synthetase II gene (glnII) from S. coelicolor. Besides glnII, this region contains four ORFs (orf1-orf4). While homologues of orf1 and orf2 were also found in the glnII region of the S. viridochromogenes chromosome, this was not the case for orf3 and orf4, which encode a putative hydrolase and a transcriptional regulator (Ptr) of the MarR family, respectively. High-resolution S1 nuclease mapping showed that the S. coelicolor glnII gene is expressed from two overlapping promoters. The first comprises a vegetative promoter sequence and the second contains sequence elements that are recognized by Esigma31. Similar promoter structures were found upstream of the S. viridochromogenes glnII gene. The involvement of ptr in glnII regulation was studied by gel retardation assays. Recombinant Ptr interacted with the upstream region of ptr, but not with the promoter region of glnII. A ptr gene replacement mutant (S. coelicolor IP) was also constructed. RT-PCR analysis of RNA from wild-type S. coelicolor and the IP mutant demonstrated that expression of orf3 depends on Ptr. Thus, the difference in gene organization between S. coelicolor and S. viridochromogenes is not responsible for the difference in GSII activity.